Press Releases

ARUP Laboratories observed Cyclospora positivity rates increase from very low levels to unprecedented levels within a short period of time, highlighting the importance of providing clinicians and laboratorians with timely disease surveillance data, said Ben Bradley, MD, PhD, ARUP head of clinical operations for Infectious Disease.

ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry characterizes small neoplastic populations with greater sensitivity than conventional flow cytometry while requiring less specimen volume.

Jonathan Genzen, MD, PhD, MBA, ARUP’s chief medical officer and senior director of governmental affairs, said the Enhancing CLIA Act is an intriguing step forward in considering future oversight of laboratory-developed tests.

ARUP Laboratories has launched the first national, multipathogen Infectious Disease Test Positivity Trends Dashboard, which provides deidentified test result positivity trends that may help clinical laboratories and medical directors identify unusual patterns, seasonal shifts, and emerging infectious disease activity sooner.

Leaders of ARUP’s Innovation Business Unit discuss their latest developments. Pictured from left to right are Hunter Best, PhD, FACMG; Tracy George, MD; Erica Clyde, MBA, PMI-PMP^®, MB(ASCP)^CM; and Salika Shakir, PhD, D(ABMM).